Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company dedicated to discovering, developing, and commercializing transformative medicines for people with serious diseases. The company's mission is to invest in scientific innovation to create these medicines, with a strategic focus on specialty markets. Vertex maintains its global headquarters in Boston, Massachusetts, located at 50 Northern Avenue.

Vertex is widely recognized for its pioneering work in cystic fibrosis (CF) treatments, with a portfolio that includes Trikafta (also known as Kaftrio outside the U.S.), Kalydeco, Orkambi, Symdeko, and Alyftrek. Beyond CF, the company has expanded its focus to other serious conditions, developing Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia in collaboration with CRISPR Therapeutics, and Journavx, a novel non-opioid medicine for acute pain. Its pipeline and market segments include APOL1-mediated kidney disease, alpha-1 antitrypsin deficiency, and type 1 diabetes.

Led by President and CEO Reshma Kewalramani, Vertex continues to advance its therapeutic pipeline and market presence. Recent notable developments include the April 2026 US FDA approval for label extensions of ALYFTREK® and TRIKAFTA®, significantly expanding their availability to approximately 95% of CF patients in the United States. The company also reported positive Phase 3 trial results for Povetacicept in IgA nephropathy in March 2026 and launched Journavx in January 2025. In April 2024, Vertex acquired Alpine Immune Sciences for $4.9 billion, further diversifying its research and development capabilities.